Domainex and Cresset form drug discovery services alliance

Domainex and Cresset Discovery Services have formed an alliance to provide their customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology.

Domainex is a Cambridge-based small-molecule drug discovery company that provides integrated drug discovery services to pharmaceutical, biotechnology and academic partners globally. Cresset Discovery Services offers a powerful combination of human expertise, computational biology and computational chemistry approaches to solve high-value problems in drug discovery.

The alliance will give clients fully-integrated access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s approach to hit identification and drug design using its proprietary computational technologies.

Commenting on the announcement, Eddy Littler, Chief Executive Officer of Domainex, said, “The combination of Domainex’s drug discovery skills and the computational chemistry technologies and expertise of Cresset means that together we can offer customers an unrivalled capability to identify novel hit compounds against important drug targets, and to progress these all the way to candidate drugs.  In particular Cresset’s patented field point technology and associated ligand-based approaches to targets such as GPCRs and ion-channels will perfectly complement Domainex’s own expertise in target areas such as enzymes and protein-protein interactions. We look forward to developing our relationship, and enhancing the success of our client programmes through the combination of our skills and competences.”  

Rob Scoffin, Chief Executive Officer of Cresset, added, “We are very excited about the opportunity to partner with another world-class research services company in order to offer unrivalled capabilities in drug discovery and development. We are able to provide integrated services which will include access to Cresset’s existing applications as well as our pipeline of cutting edge computational science and yet-to-be-commercialised methods.”